Enlivex Ltd. (NASDAQ:ENLV) Financings

Enlivex Ltd.

Financings

RaiseDate
Registered direct offering of ordinary shares (or pre-funded warrants) with accompanying ordinary warrants
Announced: US$7.5M · US$1.315 a share · Warrants at US$1.578 for 36 months
Use of proceeds: Clinical, regulatory, manufacturing and R&D activities; potential acquisitions and in-licensing; general corporate purposes
Nov 16, 2026
Private placement of ordinary shares
Cancelled: US$400M · US$6 a share
Buyers: Rain Foundation (66,666,667 ordinary shares, to be paid for using RAIN tokens (agreement terminated))
Use of proceeds: Treasury strategy built around the Rain protocol prediction markets, while continuing to advance its Allocetra immunotherapy for age-related osteoarthritis
Sep 22, 2026
Private placement of ordinary shares (or ordinary share equivalents)
Closed: US$212M raised · US$1 a share · BTIG
Dealers: BTIG (lead)
Use of proceeds: Implement a RAIN prediction markets token treasury strategy while continuing core business operations
Nov 26, 2025

Read by 6ix AI from the company's releases